
PHARMAXIS ANNOUNCES NEW BOARD APPOINTMENT

Pharmaceutical company Pharmaxis (ASX: PXS) today announced the appointment of experienced international pharmaceutical executive Dr Simon Buckingham, to its Board of Directors.

Dr Buckingham has more than 20 years experience in top tier pharmaceutical and biotechnology companies with expertise in general management, sales and marketing, clinical development, business development and corporate strategic planning.

During his career Dr Buckingham has worked across a range of therapeutic areas including cardiovascular and respiratory medicine. Most recently, he held the position of President, Global Corporate and Business Development for a large pharmaceutical company and remains affiliated with that company through a global senior advisory role.

In addition to his professional career, Dr Buckingham contributes as an advisor to a number of not-for-profit organisations.

“Pharmaxis is now an operating business with a number of projects coming to a critical point in their development,” said Pharmaxis Chairman, Mr Malcolm McComas. “Our shareholders will benefit from Dr Buckingham’s experience in the commercialisation and development of new pharmaceutical products.”

In accepting the board position Dr Buckingham said: “For a relatively new company Pharmaxis has an impressive record in research and development of new medicines and I am excited to become part of such a dynamic business. I am very much looking forward to working with the Pharmaxis Board and management team in fulfilling the company’s objectives.”

Dr Buckingham is a graduate from both the University of Sydney and the University of Melbourne and has worked extensively in both Europe and the United States.

Further information on all of the Pharmaxis board members can be found on the Pharmaxis web site.

#ends#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

RELEASED THROUGH:

Australia:

Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is sold in key international markets and its product Bronchitol® for cystic fibrosis is recently launched in Europe and Australia. Pharmaxis product pipeline of products Bronchitol for bronchiectasis, ASM8 for asthma, PXS64 for the treatment of lung fibrosis and PXS4728 for inflammation and fibrosis.

Founded in 1998, Pharmaxis is listed on the Australian Securities Exchange - symbol PXS. The company is headquartered in Sydney at its TGA-approved manufacturing facilities.

For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive regulatory approval or that we will seek any such approval.